4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 33 Issue 3
Apr.  2019
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Hardy-Rando Eugenio, Fernandez-Patron Carlos. Emerging pathways of communication between the heart and non-cardiac organs[J]. The Journal of Biomedical Research, 2019, 33(3): 145-155. DOI: 10.7555/JBR.32.20170137
Citation: Hardy-Rando Eugenio, Fernandez-Patron Carlos. Emerging pathways of communication between the heart and non-cardiac organs[J]. The Journal of Biomedical Research, 2019, 33(3): 145-155. DOI: 10.7555/JBR.32.20170137
shu

Emerging pathways of communication between the heart and non-cardiac organs

  • 1.

    Biotechnology Laboratory, Study Center for Research and Biological Evaluations, Institute of Pharmacy and Foods, University of Havana, Havana PO Box 430, Cuba

  • 2.

    Department of Biochemistry, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada

More Information
  • Corresponding author:

    Carlos Fernandez-Patron, Department of Biochemistry, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, 3-19 Medical Sciences Building, University of Alberta, Edmonton, AB T6G 2H7, Canada. Tel: 780-492-9540/780-492-7618, E-mail: cf2@ualberta.ca

  • Received Date: December 20, 2017
  • Revised Date: February 10, 2018
  • Accepted Date: February 18, 2018
  • Available Online: March 27, 2018
    Graphical Abstract
    • Abstract
  • The breakthrough discovery of cardiac natriuretic peptides provided the first direct demonstration of the connection between the heart and the kidneys for the maintenance of sodium and volume homeostasis in health and disease. Yet, little is still known about how the heart and other organs cross-talk. Here, we review three physiological mechanisms of communication linking the heart to other organs through: ⅰ) cardiac natriuretic peptides, ⅱ) the microRNA-208a/ mediator complex subunit-13 axis and ⅲ) the matrix metalloproteinase-2 (MMP-2)/C-C motif chemokine ligand-7/ cardiac secreted phospholipase A2 (sPLA2) axis – a pathway which likely applies to the many cytokines, which are cleaved and regulated by MMP-2. We also suggest experimental strategies to answer still open questions on the latter pathway. In short, we review evidence showing how the cardiac secretome influences the metabolic and inflammatory status of non-cardiac organs as well as the heart.
    • FullText(HTML)
    • References (59)
  • [1]
    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 385(9963): 117-171. doi: 10.1016/S0140-6736(14)61682-2
    [2]
    de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats[J]. Life Sci, 1981, 28(1): 89-94. doi: 10.1016/0024-3205(81)90370-2
    [3]
    de Bold AJ, Salerno TA. Natriuretic activity of extracts obtained from hearts of different species and from various rat tissues[J]. Can J Physiol Pharmacol, 1983, 61(2): 127-130. doi: 10.1139/y83-018
    [4]
    de Bold AJ, Flynn TG. Cardionatrin I- a novel heart peptide with potent diuretic and natriuretic properties[J]. Life Sci, 1983, 33(3): 297-302. doi: 10.1016/0024-3205(83)90390-9
    [5]
    Flynn TG, Davies PL, Kennedy BP, et al. Alignment of rat cardionatrin sequences with the preprocardionatrin sequence from complementary DNA[J]. Science, 1985, 228(4697): 323- 325. doi: 10.1126/science.3157217
    [6]
    Grueter CE, van Rooij E, Johnson BA, et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13[J]. Cell, 2012, 149(3): 671-683. doi: 10.1016/j.cell.2012.03.029
    [7]
    Berry E, Hernandez-Anzaldo S, Ghomashchi F, et al. Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate inflammation and fever[J]. J Am Heart Assoc, 2015, 4(4): e001868. http://cn.bing.com/academic/profile?id=0a330cd5b19da9f1facf66e1c49bb152&encoded=0&v=paper_preview&mkt=zh-cn
    [8]
    Hernandez-Anzaldo S, Berry E, Brglez V, et al. Identification of a novel heart-liver axis: matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate lipid metabolism and inflammation in the liver[J]. J Am Heart Assoc, 2015, 4(11): e002553. http://cn.bing.com/academic/profile?id=623168e4f29ceca9a7440a5d95ac7f77&encoded=0&v=paper_preview&mkt=zh-cn
    [9]
    Wang X, Berry E, Hernandez-Anzaldo S, et al. Matrix metalloproteinase-2 mediates a mechanism of metabolic cardioprotection consisting of negative regulation of the sterol regulatory element-binding protein-2/3-hydroxy-3-methylglutaryl-CoA reductase pathway in the heart[J]. Hypertension, 2015, 65(4):882-888. doi: 10.1161/HYPERTENSIONAHA.114.04989
    [10]
    Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain[J]. Nature, 1988, 332(6159): 78-81. doi: 10.1038/332078a0
    [11]
    Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes[J]. Am J Hypertens, 1991, 4(11): 909-912. doi: 10.1093/ajh/4.11.909
    [12]
    Clerico A, Giannoni A, Vittorini S, et al. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones[J]. Am J Physiol Heart Circ Physiol, 2011, 301(1): H12-H20. doi: 10.1152/ajpheart.00226.2011
    [13]
    Del Ry S, Cabiati M, Vozzi F, et al. Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes[J]. Peptides, 2011, 32(8): 1713-1718. doi: 10.1016/j.peptides.2011.06.014
    [14]
    Ogawa T, de Bold AJ. The heart as an endocrine organ[J]. Endocr Connect, 2014, 3(2): R31-R44. doi: 10.1530/EC-14-0012
    [15]
    Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular disease[J]. Clin Sci (Lond), 1998, 95(5): 519-529. doi: 10.1042/cs0950519
    [16]
    Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health[J]. Clin Sci (Lond), 2005, 108(1): 23-36. doi: 10.1042/CS20040253
    [17]
    Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure[J]. Circulation, 1993, 88(3): 1004-1009. doi: 10.1161/01.CIR.88.3.1004
    [18]
    Del Ry S, Passino C, Maltinti M, et al. C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity[J]. Eur J Heart Fail, 2005, 7(7): 1145-1148. doi: 10.1016/j.ejheart.2004.12.009
    [19]
    Mangat H, de Bold AJ. Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormone[J]. Endocrinology, 1993, 133(3): 1398-1403. doi: 10.1210/endo.133.3.8365374
    [20]
    Arvan P, Kuliawat R, Prabakaran D, et al. Protein discharge from immature secretory granules displays both regulated and constitutive characteristics[J]. J Biol Chem, 1991, 266(22): 14171-14174. http://cn.bing.com/academic/profile?id=3d1917dc526ada35fdcd43ca12faa001&encoded=0&v=paper_preview&mkt=zh-cn
    [21]
    Gerzer R, Witzgall H, Tremblay J, et al. Rapid increase in plasma and urinary cyclic GMP after bolus injection of atrial natriuretic factor in man. J Clin Endocrinol Metab, 1985, 61(6): 1217-1219. doi: 10.1210/jcem-61-6-1217
    [22]
    Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins[J]. FASEB J, 1993, 7(2): 328-338. doi: 10.1096/fasebj.7.2.7680013
    [23]
    Melo LG, Steinhelper ME, Pang SC, et al. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models[J]. Physiol Genomics, 2000, 3(1): 45- 58. doi: 10.1152/physiolgenomics.2000.3.1.45
    [24]
    Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects[J]. Eur J Heart Fail, 2004, 6(3): 261-268. doi: 10.1016/j.ejheart.2004.01.004
    [25]
    Wiley KE, Davenport AP. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery[J]. Br J Pharmacol, 2001, 133(4): 568-574. doi: 10.1038/sj.bjp.0704119
    [26]
    Furuya M, Yoshida M, Hayashi Y, et al. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells[J]. Biochem Biophys Res Commun, 1991, 177(3): 927-931. doi: 10.1016/0006-291X(91)90627-J
    [27]
    Franco-Saenz R, Atarashi K, Takagi M, et al. Effect of atrial natriuretic factor on renin and aldosterone[J]. J Cardiovasc Pharmacol, 1989, 13(Suppl 6): S31-S35. http://cn.bing.com/academic/profile?id=760f36823fa43a7e0f837c2f82c4bc8d&encoded=0&v=paper_preview&mkt=zh-cn
    [28]
    Brenner BM, Ballermann BJ, Gunning ME, et al. Diverse biological actions of atrial natriuretic peptide[J]. Physiol Rev, 1990, 70(3): 665-699. doi: 10.1152/physrev.1990.70.3.665
    [29]
    Burger AJ. A review of the renal and neurohormonal effects of B-type natriuretic peptide[J]. Congest Heart Fail, 2005, 11(1): 30-38. doi: 10.1111/chf.2005.11.issue-1
    [30]
    Sengenès C, Berlan M, De Glisezinski I, et al. Natriuretic peptides: a new lipolytic pathway in human adipocytes[J]. FASEB J, 2000, 14(10): 1345-1351. doi: 10.1096/fasebj.14.10.1345
    [31]
    Sengenes C, Stich V, Berlan M, et al. Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women[J]. FASEB J, 2000, 14(10): 1345-1351. doi: 10.1096/fasebj.14.10.1345
    [32]
    Sengenès C, Zakaroff-Girard A, Moulin A, et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity[J]. Am J Physiol Regul Integr Comp Physiol, 2002, 283(1): R257-R265. doi: 10.1152/ajpregu.00453.2001
    [33]
    Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone sensitive lipase phosphorylation in human adipocytes[J]. J Biol Chem, 2003, 278(49):48617-48626. doi: 10.1074/jbc.M303713200
    [34]
    Galitzky J, Sengenès C, Thalamas C, et al. The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men[J]. J Lipid Res, 2001, 42(4): 536-544. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_ab553f32c343e3e743a5f041c67677d5
    [35]
    Sarzani R, Marcucci P, Salvi F, et al. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth[J]. Int J Obes, 2008, 32(2): 259-267. doi: 10.1038/sj.ijo.0803724
    [36]
    Pierkes M, Gambaryan S, Bokník P, et al. Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice[J]. Cardiovasc Res, 2002, 53(4): 852-861. doi: 10.1016/S0008-6363(01)00543-0
    [37]
    Brusq JM, Mayoux E, Guigui L, et al. Effects of C-type natriuretic peptide on rat cardiac contractility[J]. Br J Pharmacol, 1999, 128(1): 206-212. doi: 10.1038/sj.bjp.0702766
    [38]
    Beaulieu P, Cardinal R, Pagé P, et al. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs[J]. Am J Physiol, 1997, 273(4 Pt 2): H1933-H1940.
    [39]
    Tokudome T, Horio T, Soeki T, et al. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways[J]. Endocrinology, 2004, 145(5): 2131- 2140. doi: 10.1210/en.2003-1260
    [40]
    Santhekadur PK, Kumar DP, Seneshaw M, et al. The multifaceted role of natriuretic peptides in metabolic syndrome[J]. Biomed Pharmacother, 2017, 92: 826-835. doi: 10.1016/j.biopha.2017.05.136
    [41]
    Schlueter N, de Sterke A, Willmes DM, et al. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome[J]. Pharmacol Ther, 2014, 144(1): 12-27. doi: 10.1016/j.pharmthera.2014.04.007
    [42]
    Moro C. Natriuretic peptides and fat metabolism[J]. Curr Opin Clin Nutr Metab Care, 2013, 16(6): 645-649. doi: 10.1097/MCO.0b013e32836510ed
    [43]
    Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research[J]. Diabetes Care, 2014, (11):2899-2908.
    [44]
    Wang D, Oparil S, Feng JA, et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse[J]. Hypertension, 2003, 42(1): 88-95. doi: 10.1161/01.HYP.0000074905.22908.A6
    [45]
    Vellaichamy E, Khurana ML, Fink J, et al. Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A[J]. J Biol Chem, 2005, 280(19): 19230-19242. doi: 10.1074/jbc.M411373200
    [46]
    Subramanian U, Kumar P, Mani I, et al. Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 genedisrupted haplotype mice[J]. Physiol Genomics, 2016, 48(7): 477-490. doi: 10.1152/physiolgenomics.00073.2015
    [47]
    Sarzani R, Salvi F, Dessì-Fulgheri P, et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans[J]. J Hypertens, 2008, 26(5): 831-843. doi: 10.1097/HJH.0b013e3282f624a0
    [48]
    Clerico A, Giannoni A, Vittorini S, et al. The paradox of low BNP levels in obesity[J]. Heart Fail Rev, 2012, 17(1): 81- 96. doi: 10.1007/s10741-011-9249-z
    [49]
    Moro C. Targeting cardiac natriuretic peptides in the therapy of diabetes and obesity[J]. Expert Opin Ther Targets, 2016, 20(12): 1445-1452. doi: 10.1080/14728222.2016.1254198
    [50]
    Baskin KK, Grueter CE, Kusminski CM, et al. MED13- dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver[J]. EMBO Mol Med, 2014, 6(12): 1610-1621. doi: 10.15252/emmm.201404218
    [51]
    Lee JH, Bassel-Duby R, Olson EN. Heart- and muscle-derived signaling system dependent on MED13 and Wingless controls obesity in Drosophila[J]. Proc Natl Acad Sci USA, 2014, 111(26): 9491-9496. doi: 10.1073/pnas.1409427111
    [52]
    Konzer A, Ruhs A, Braun T, et al. Global protein quantification of mouse heart tissue based on the SILAC mouse[J]. Methods Mol Biol, 2013, 1005: 39-52. doi: 10.1007/978-1-62703-386-2
    [53]
    Zanivan S, Krueger M, Mann M. In vivo quantitative proteomics: the SILAC mouse[J]. Methods Mol Biol, 2012, 757: 435-450. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_2953914
    [54]
    Gioia M, Foster LJ, Overall CM. Cell-based identification of natural substrates and cleavage sites for extracellular proteases by SILAC proteomics[J]. Methods Mol Biol, 2009, 539: 131- 153. doi: 10.1007/978-1-60327-003-8
    [55]
    Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics[J]. Mol Cell Proteomics, 2002, 1(5): 376-386. doi: 10.1074/mcp.M200025-MCP200
    [56]
    Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation[J]. Nat Immunol, 2001, 2(2): 102-107. doi: 10.1038/84205
    [57]
    White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation-therapeutic opportunities and pharmacological challenges[J]. Pharmacol Rev, 2013, 65(1): 47-89. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0234029364/
    [58]
    Steinberg GR, Michell BJ, van Denderen BJ, et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling[J]. Cell Metab, 2006, 4(6): 465-474. doi: 10.1016/j.cmet.2006.11.005
    [59]
    Tse MCL, Herlea-Pana O, Brobst D, et al. Tumor necrosis factor-alpha promotes phosphoinositide 3-kinase enhancer A and AMP-activated protein kinase interaction to suppress lipid oxidation in skeletal muscle[J]. Diabetes, 2017, 66(7): 1858- 1870. doi: 10.2337/db16-0270
    • Related Articles

  • Related Articles

    [1]Yuetong Chen, Chen Li, Yi Shi, Jiali Dai, Yixuan Meng, Shuwei Li, Cuiju Tang, Dongying Gu, Jinfei Chen. Identification of common genetic variants in KCNQ family genes associated with gastric cancer survival in a Chinese population[J]. The Journal of Biomedical Research, 2025, 39(1): 76-86. DOI: 10.7555/JBR.38.20240040
    [2]Yujuan Zhang, Kai Lu, Xu Wu, Hanting Liu, Junyi Xin, Xiaowei Wang, Weida Gong, Qinghong Zhao, Meilin Wang, Haiyan Chu, Mulong Du, Guoquan Tao, Zhengdong Zhang. Genetic variants in the Hedgehog signaling pathway genes are associated with gastric cancer risk in a Chinese Han population[J]. The Journal of Biomedical Research, 2022, 36(1): 22-31. DOI: 10.7555/JBR.35.20210091
    [3]Qiu Jinchun, Guo Hongli, Li Ling, Xu Zeyue, Xu Zejun, Jing Xia, Hu Yahui, Wen Xiaoyi, Chen Feng, Lu Xiaopeng. Valproic acid therapy decreases serum 25-hydroxyvitamin D level in female infants and toddlers with epilepsy— a pilot longitudinal study[J]. The Journal of Biomedical Research, 2021, 35(1): 61-67. DOI: 10.7555/JBR.34.20200057
    [4]Ma Hongxia, Shen Hongbing. From human genome epidemiology to systems epidemiology: current progress and future perspective[J]. The Journal of Biomedical Research, 2020, 34(5): 323-327. DOI: 10.7555/JBR.34.20200027
    [5]Naureen Javeed, Debabrata Mukhopadhyay. Exosomes and their role in the micro-/macro-environment: a comprehensive review[J]. The Journal of Biomedical Research, 2017, 31(5): 386-394. DOI: 10.7555/JBR.30.20150162
    [6]So-Hye Hong, Jae-Eon Lee, Hong Sung Kim, Young-Jin Jung, DaeYoun Hwang, Jae Ho Lee, Seung Yun Yang, Seung-Chul Kim, Seong-Keun Cho, Beum-Soo An. Effect of vitamin D3 on production of progesterone in porcine granulosa cells by regulation of steroidogenic enzymes[J]. The Journal of Biomedical Research, 2016, 30(3): 203-208. DOI: 10.7555/JBR.30.2016K0012
    [7]Rezvan Hashemi, Sakineh Shab Bidar, Moloud Payab, Ramin Heshmat, Ahmad Reza Dorosti-Motlagh. Urgent need of vitamin D supplementation among Iranian elderly: a cross-sectional study[J]. The Journal of Biomedical Research, 2014, 28(6): 509-512. DOI: 10.7555/JBR.28.20140089
    [8]Nuan Wang, Xianming Chen, Deqin Geng, Hongli Huang, Hao Zhou. Ginkgo biloba leaf extract improves the cognitive abilities of rats with D-galactose induced dementia[J]. The Journal of Biomedical Research, 2013, 27(1): 29-36. DOI: 10.7555/JBR.27.20120047
    [9]Min Zhang, Yan Zhang, Shuaishuai Zhu, Xiaoyu Li, Qing Yang, Hui Bai, Qi Chen. Genetic variants of the class A scavenger receptor gene are associated with coronary artery disease in Chinese[J]. The Journal of Biomedical Research, 2012, 26(6): 418-424. DOI: 10.7555/JBR.26.20110116
    [10]Hua Huang, Juan Wu, Guangfu Jin, Hanze Zhang, Yanbing Ding, Zhaolai Hua, Yan Zhou, Yan Xue, Yan Lu, Zhibin Hu, Yaochu Xu, Hongbing Shen. A 5'-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population[J]. The Journal of Biomedical Research, 2010, 24(2): 100-106.

  • Cited by

    Periodical cited type(27)

    1. Boda VK, Yasmen N, Jiang J, et al. Pathophysiological significance and modulation of the transient receptor potential canonical 3 ion channel. Med Res Rev, 2024, 44(6): 2510-2544. DOI:10.1002/med.22048
    2. Agrawal K, Asthana S, Kumar D. Role of Oxidative Stress in Metabolic Reprogramming of Brain Cancer. Cancers (Basel), 2023, 15(20): 4920. DOI:10.3390/cancers15204920
    3. Zhou Y, Pereira G, Tang Y, et al. 3D Porous Scaffold-Based High-Throughput Platform for Cancer Drug Screening. Pharmaceutics, 2023, 15(6): 1691. DOI:10.3390/pharmaceutics15061691
    4. Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces. Cancer Drug Resist, 2022, 5(4): 850-872. DOI:10.20517/cdr.2022.20
    5. Gal O, Betzer O, Rousso-Noori L, et al. Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy. J Nanotheranostics, 2022, 3(4): 177-188. DOI:10.3390/jnt3040012
    6. Scioli MG, Terriaca S, Fiorelli E, et al. Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives. Int J Mol Sci, 2021, 22(19): 10572. DOI:10.3390/ijms221910572
    7. Keyvani-Ghamsari S, Khorsandi K, Rasul A, et al. Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. Clin Epigenetics, 2021, 13(1): 120. DOI:10.1186/s13148-021-01107-4
    8. Safa AR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci, 2020, 6(3): 341. DOI:10.15761/jts.1000341
    9. Chandimali N, Koh H, Kim J, et al. BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer. Oncol Lett, 2020, 20(4): 103. DOI:10.3892/ol.2020.11964
    10. Mukherjee S. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples. Sci Rep, 2020, 10(1): 10937. DOI:10.1038/s41598-020-67753-5
    11. Zhou JJ, Xiao Y, Li H, et al. Overexpression of Malic Enzyme 2 Indicates Pathological and Clinical Significance in Oral Squamous Cell Carcinoma. Int J Med Sci, 2020, 17(6): 799-806. DOI:10.7150/ijms.43832
    12. Sun Z, Wang L, Zhou Y, et al. Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein. Cell Mol Neurobiol, 2020, 40(5): 767-784. DOI:10.1007/s10571-019-00771-8
    13. Zhang Q, Xu B, Chen J, et al. Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. J Clin Lab Anal, 2020, 34(3): e23082. DOI:10.1002/jcla.23082
    14. Megías J, Martínez A, San-Miguel T, et al. Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide. Invest New Drugs, 2020, 38(2): 299-310. DOI:10.1007/s10637-019-00788-2
    15. Li Z, Chen Y, An T, et al. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway. J Exp Clin Cancer Res, 2019, 38(1): 139. DOI:10.1186/s13046-019-1134-y
    16. Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med, 2018, 7(1): 33. DOI:10.1186/s40169-018-0211-8
    17. Grande S, Palma A, Ricci-Vitiani L, et al. Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs. Stem Cells Int, 2018, 2018: 3292704. DOI:10.1155/2018/3292704
    18. Zuccarini M, Giuliani P, Ziberi S, et al. The Role of Wnt Signal in Glioblastoma Development and Progression: A Possible New Pharmacological Target for the Therapy of This Tumor. Genes (Basel), 2018, 9(2): 105. DOI:10.3390/genes9020105
    19. Bhere D, Tamura K, Wakimoto H, et al. microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis. Neuro Oncol, 2018, 20(2): 215-224. DOI:10.1093/neuonc/nox138
    20. Lee S, Kwon MC, Jang JP, et al. The ginsenoside metabolite compound K inhibits growth, migration and stemness of glioblastoma cells. Int J Oncol, 2017, 51(2): 414-424. DOI:10.3892/ijo.2017.4054
    21. Jovčevska I, Zupanec N, Urlep Ž, et al. Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget, 2017, 8(27): 44141-44158. DOI:10.18632/oncotarget.17390
    22. Hiramatsu H, Kobayashi K, Kobayashi K, et al. The role of the SWI/SNF chromatin remodeling complex in maintaining the stemness of glioma initiating cells. Sci Rep, 2017, 7(1): 889. DOI:10.1038/s41598-017-00982-3
    23. Zheng X, Pang B, Gu G, et al. Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis. Int J Biol Sci, 2017, 13(2): 245-253. DOI:10.7150/ijbs.16818
    24. Bijangi-Vishehsaraei K, Reza Saadatzadeh M, Wang H, et al. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. J Neurosurg, 2017, 127(6): 1219-1230. DOI:10.3171/2016.8.JNS161197
    25. Majewska E, Szeliga M. AKT/GSK3β Signaling in Glioblastoma. Neurochem Res, 2017, 42(3): 918-924. DOI:10.1007/s11064-016-2044-4
    26. Kanabur P, Guo S, Simonds GR, et al. Patient-derived glioblastoma stem cells respond differentially to targeted therapies. Oncotarget, 2016, 7(52): 86406-86419. DOI:10.18632/oncotarget.13415
    27. Wang K, Kievit FM, Erickson AE, et al. Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells. Adv Healthc Mater, 2016, 5(24): 3173-3181. DOI:10.1002/adhm.201600684

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article has an altmetric score of 1
    Article has an altmetric score of 1
    Article views PDF downloads Cited by(27)
    Related

    ©2023 by the Editorial Department of the Journals of Nanjing Medical University. All rights reserved.   苏ICP备05071376号-5

    Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail: info@rhhz.net  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return